Literature DB >> 15378492

Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.

Dora L W Kwong1, Edmond H N Pow, Jonathan S T Sham, Anne S McMillan, Lucullus H T Leung, W Keung Leung, Daniel T T Chua, Ashley C K Cheng, Po M Wu, Gordon K H Au.   

Abstract

BACKGROUND: Xerostomia is a uniform complication after radiotherapy (RT) for nasopharyngeal carcinoma (NPC). Dosimetric studies suggested that intensity-modulated RT (IMRT) can spare part of the parotid glands from high-dose radiation. Disease control and salivary function after IMRT for early-stage NPC was studied prospectively.
METHODS: Thirty-three patients with T1,N0-N1,M0 NPC were treated with IMRT from 2000 to 2002. The prescribed dose was 68-70 grays (Gy) in 34 fractions to gross tumor volume, 64-68 Gy to the planning target volume, and 70 Gy to enlarged cervical lymph nodes. Nineteen patients had stimulated whole salivary (SWS) flow assessment and stimulated parotid salivary (SPS) flow assessment at baseline and at 2 months, 6 months, 12 months, 18 months, and 24 months after the completion of IMRT.
RESULTS: At a median follow-up of 2 years, only 1 neck failure was observed. The 2-year and 3-year local control, distant metastases-free, and overall survival rates all were 100%. The lymph node control and progression-free survival rates were 100% at 2 years and 92.3% at 3 years, respectively. The average mean dose to the parotid gland was 38.8 Gy. The SWS and SPS flow showed continuous recovery: 60% and 47.1% of patients recovered at least 25% of their baseline SPS flow and SWS flow, respectively, at 1 year after completion of IMRT, and the proportions rose to 85.7% and 71.4%, respectively, by 2 years. The pH and buffering capacity of saliva also improved with time.
CONCLUSIONS: Parotid-sparing IMRT achieved good locoregional control, and there was continuous recovery of salivary flow, pH, and buffering capacity in the first 2 years after IMRT in patients with NPC. (c) 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 15378492     DOI: 10.1002/cncr.20552

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  66 in total

Review 1.  Assessment of post-radiotherapy salivary glands.

Authors:  S C H Cheng; V W C Wu; D L W Kwong; M T C Ying
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

2.  Investigations on parotid gland recovery after IMRT in head and neck tumor patients.

Authors:  Markus Stock; Wolfgang Dörr; Carmen Stromberger; Ulrike Mock; Susanne Koizar; Richard Pötter; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

Review 3.  Clinical application of intensity-modulated radiotherapy for head and neck cancer.

Authors:  O Ballivy; R Galiana Santamaría; A Lozano Borbalas; F Guedea Edo
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

4.  Superficial parotid lobe-sparing delineation approach: a better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma.

Authors:  H B Zhang; X Lu; S M Huang; L Wang; C Zhao; W X Xia; S W Li; F L Wang; Y L Zhu; X Guo; Y Q Xiang
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

5.  Magnetic resonance sialography for investigating major salivary gland duct system after intensity-modulated radiotherapy of nasopharyngeal carcinoma.

Authors:  Dan Ou; Yunyan Zhang; Xiayun He; Yajia Gu; Chaosu Hu; Hongmei Ying; Guopei Zhu; Yongru Wu; Jian Mao; Lei Yue; Xigang Shen
Journal:  Int J Clin Oncol       Date:  2012-08-15       Impact factor: 3.402

6.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

7.  Alternative endpoints to the 5-year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients.

Authors:  Chen Chen; Wei Yi; Jin Gao; Xiao-Hui Li; Lu-Jun Shen; Bo-Fei Li; Zi-Wei Tu; Ya-Lan Tao; Chang-Bin Jiang; Yun-Fei Xia
Journal:  Mol Clin Oncol       Date:  2014-02-20

8.  An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.

Authors:  Quynh-Thu Le; Qiang Zhang; Hongbin Cao; Ann-Joy Cheng; Benjamin A Pinsky; Ruey-Long Hong; Joseph T Chang; Chun-Wei Wang; Kuo-Chien Tsao; Ym Dennis Lo; Nancy Lee; K Kian Ang; Anthony T C Chan; K C Allen Chan
Journal:  Clin Cancer Res       Date:  2013-03-04       Impact factor: 12.531

9.  Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.

Authors:  Shaojun Lin; Jiade Jay Lu; Lu Han; Qisong Chen; Jianji Pan
Journal:  BMC Cancer       Date:  2010-02-10       Impact factor: 4.430

10.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.